centerforbiosimilars12h
Eye on Pharma: Teva, Formycon, Celltrion Biosimilar Updates in Global Markets
Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...
centerforbiosimilars1d
Prateek Yadav, MPTh, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars1d
Chase Ibia, PharmD Candidate
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars1d
No Disease Activity Changes After Children With IBD Switched to Infliximab Biosimilar
A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant ...
centerforbiosimilars2d
Courtney Flaherty
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2d
Dracey Poore
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars3d
The Top 5 Biosimilar Articles for the Week of January 20
Number 5: The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the ...
centerforbiosimilars3d
Robert Spina, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars4d
Christina Corridon, MPH, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars4d
Mayuri Mathuria, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars4d
Cost-Benefits, Efficacy of Biosimilar Ranibizumab vs Aflibercept for nAMD in Japan
When compared with reference aflibercept, a biosimilar ranibizumab was a clinically effective and cost-saving alternative in ...